Bausch + Lomb Initiates Phase 2b Study With Glaucoma Drug Candidate
NicOx S.A. today announced that its partner Bausch + Lomb has initiated a phase 2b clinical study with BOL-303259-X, previously known as NCX 116. BOL-303259-X is a nitric oxide-donating prostaglandin F2-alpha analog, which lowers intraocular pressure...